Previous 10 | Next 10 |
The following slide deck was published by UroGen Pharma Ltd. in conjunction with this Read more ...
UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that Liz Barrett, President and Chief Executive Officer, will present at the Jefferies Virtual Healthcar...
Cassava Sciences Stock Slumps After Alzheimer's Trial Miss Cassava Sciences Inc.'s ( SAVA ) stock crashed as the company reported topline data from its mid-stage trial of its Alzheimer’s drug candidate. The Phase 2b study aimed to assess the potential of PTI-125 in treating patien...
UroGen Pharma Ltd. ( URGN ) announces positive preliminary results from a Phase 2b clinical trial, OPTIMA II , evaluating UGN-102 (mitomycin) for intravesical (placed directly in the bladder) solution in patients with low-grade intermediate risk non-muscle invasive bladder cancer. The dat...
65% Complete Response in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer Of Patients who Achieved a Complete Response and Underwent an Evaluation at Each Timepoint, 97%, 86% and 85% Remained Disease Free at Six, Nine and 12 Months Following Initiation of...
UroGen Pharma Ltd. (Nasdaq:URGN) today announced the presentation of positive data from the UGN-101 ( Jelmyto™ (mitomycin) for pyelocalyceal solution) Phase 3 OLYMPUS trial in patients with low-grade upper tract urothelial cancer (LG-UTUC). The study was accepted for the 2020 Americ...
UroGen Pharma Ltd. (URGN) Q1 2020 Earnings Conference Call May 7, 2020 08:30 ET Company Participants Kate Bechtold - Senior Director, Investor Relations Liz Barrett - President & Chief Executive Officer Mark Schoenberg - Chief Medical Officer Jeff Bova - Senior Vice Preside...
Image source: The Motley Fool. UroGen Pharma Ltd. (NASDAQ: URGN) Q1 2020 Earnings Call May 9, 2020 , 8:30 p.m. ET Operator Continue reading
UroGen Pharma (NASDAQ: URGN ): Q1 GAAP EPS of -$1.79 misses by $0.17 . More news on: UroGen Pharma Ltd., Earnings news and commentary, Healthcare stocks news, Read more ...
Received U.S. FDA Approval for Jelmyto™, the First and Only Non-Surgical Treatment for Patients with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC) Jelmyto Launch on Track for June 1, 2020 Reported UGN-102 Phase 2b Trial Interim Data with 65% Complete Response at Three ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-15 04:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-25 07:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the pricing of an underwritten public offering of 5,000,000 ordinary shares at a price to the public of $17.50 per ord...